[{"data":1,"prerenderedAt":27},["ShallowReactive",2],{"$flzBTmmssf1lLOgbh1dNhRRoj1PaoeIRXYeYEs1b6Mg0":3},{"card":4,"examId":6,"chapterTitle":24,"prev":25,"next":26},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":17,"lectureRef":18,"storyRef":18,"chapterSlug":19,"sectionCode":20,"sectionTitle":21,"clusterSlug":22,"term":18,"sequenceOrder":18,"regionWeight":18,"revisionMark":18,"isActive":23},"ch1-106","touhan","サリドマイドの催奇形性を引き起こすのはどちらの光学異性体か。",1,[10,11,12,13],"R体のみ","S体のみ","R体とS体の両方","光学異性体とは無関係である","four","サリドマイドの成分のうち、血管の形成を妨げて先天異常（催奇形性）を引き起こすのは「S体」のみです。","ただし、安全とされる「R体」だけを製剤化して飲んだとしても、体内で「S体」に変わってしまう（相互転換する）ため、催奇形性を防ぐことはできません。","「R体が催奇形性」または「R体を分離すれば安全」とする選択肢は、非常によく出る引っかけ問題です。",null,"chapter-1","1-IV","薬害の歴史","yakugai-rekishi",true,"第1章 医薬品に共通する特性と基本的な知識","ch1-105","ch1-107",1784619073873]